LONDON--(BUSINESS WIRE)--Technavio has been monitoring the autologous cell therapy market and it is poised to grow by USD 1.97 billion during 2020-2024, progressing at a CAGR of 22% during the forecast period. The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.
Technavio suggests three forecast scenarios (optimistic, probable, and pessimistic) considering the impact of COVID-19. Please Request Free Sample Report on COVID-19 Impact
Frequently Asked Questions-
- At what CAGR is the market projected to grow in the forecast period 2020-2024?
-
Growing at a CAGR of almost 22%, the market growth will accelerate in the forecast period of 2020-2024.
- What is the key factor driving the market?
-
Use of biomass as a fuel in boiler is one of the key factors driving the market growth.
- What are the top players in the market?
-
Bayer AG, Brainstorm Cell Therapeutics Inc., Daiichi Sankyo Co. Ltd., FUJIFILM Holdings Corp., Holostem Terapie Avanzate Srl, Osiris Therapeutics Inc., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Sumitomo Chemical Co. Ltd., and Vericel Corp. are some of the major market participants.
- Which region is expected to hold the highest market share?
-
North America
- What is the major trend of the market?
-
Increasing demand for effective drugs for cardiac and degenerative disorders is a major growth factor for the market.
- What is the year-over-year growth rate of the global market?
- The year-over year growth rate for 2020 is estimated at 21.70%.
The market is fragmented, and the degree of fragmentation will accelerate during the forecast period. Bayer AG, Brainstorm Cell Therapeutics Inc., Daiichi Sankyo Co. Ltd., FUJIFILM Holdings Corp., Holostem Terapie Avanzate Srl, Osiris Therapeutics Inc., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Sumitomo Chemical Co. Ltd., and Vericel Corp. are some of the major market participants. The use of biomass as a fuel in boiler will offer immense growth opportunities. To make the most of the opportunities, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
Use of biomass as a fuel in boiler has been instrumental in driving the growth of the market.
Autologous Cell Therapy Market 2020-2024: Segmentation
Autologous Cell Therapy Market is segmented as below:
-
Therapy
- Autologous Stem Cell Therapy
- Autologus Cellular Immunotherapies
-
Application
- Oncology
- Musculoskeletal Disorders
- Dermatology
-
Geography
- North America
- Europe
- APAC
- South America
- MEA
To learn more about the global trends impacting the future of market research, download a free sample: https://www.technavio.com/talk-to-us?report=IRTNTR41330
Autologous Cell Therapy Market 2020-2024: Scope
Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources. Our autologous cell therapy market report covers the following areas:
- Autologous Cell Therapy Market size
- Autologous Cell Therapy Market trends
- Autologous Cell Therapy Market analysis
This study identifies increasing demand for effective drugs for cardiac and degenerative disorders as one of the prime reasons driving the autologous cell therapy market growth during the next few years.
Autologous Cell Therapy Market 2020-2024: Vendor Analysis
We provide a detailed analysis of vendors operating in the autologous cell therapy market, including some of the vendors such as Bayer AG, Brainstorm Cell Therapeutics Inc., Daiichi Sankyo Co. Ltd., FUJIFILM Holdings Corp., Holostem Terapie Avanzate Srl, Osiris Therapeutics Inc., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Sumitomo Chemical Co. Ltd., and Vericel Corp. Backed with competitive intelligence and benchmarking, our research reports on the autologous cell therapy market are designed to provide entry support, customer profile and M&As as well as go-to-market strategy support.
Register for a free trial today and gain instant access to 17,000+ market research reports. Technavio's SUBSCRIPTION platform
Autologous Cell Therapy Market 2020-2024: Key Highlights
- CAGR of the market during the forecast period 2020-2024
- Detailed information on factors that will assist autologous cell therapy market growth during the next five years
- Estimation of the autologous cell therapy market size and its contribution to the parent market
- Predictions on upcoming trends and changes in consumer behavior
- The growth of the autologous cell therapy market
- Analysis of the market’s competitive landscape and detailed information on vendors
- Comprehensive details of factors that will challenge the growth of autologous cell therapy market vendors
Table of Contents:
Executive Summary
- Market Overview
Market Landscape
- Market ecosystem
- Value chain analysis
Market Sizing
- Market definition
- Market segment analysis
- Market size 2019
- Market outlook: Forecast for 2019 - 2024
Five Forces Analysis
- Bargaining power of buyers
- Bargaining power of suppliers
- Threat of new entrants
- Threat of substitutes
- Threat of rivalry
- Market condition
Market Segmentation by Therapy
- Market segments
- Comparison by Therapy placement
- Autologous stem cell therapy - Market size and forecast 2019-2024
- Autologous cellular immunotherapies - Market size and forecast 2019-2024
- Market opportunity by Therapy
Customer landscape
- Overview
Geographic Landscape
- Geographic segmentation
- Geographic comparison
- North America - Market size and forecast 2019-2024
- Europe - Market size and forecast 2019-2024
- APAC - Market size and forecast 2019-2024
- South America - Market size and forecast 2019-2024
- MEA - Market size and forecast 2019-2024
- Key leading countries
- Market opportunity by geography
Drivers, Challenges, and Trends
- Market drivers
- Volume driver - Demand led growth
- Volume driver - Supply led growth
- Volume driver - External factors
- Volume driver - Demand shift in adjacent markets
- Price driver - Inflation
- Price driver - Shift from lower to higher-priced units
- Market challenges
- Market trends
Vendor Landscape
- Overview
- Landscape disruption
- Vendor Analysis
Vendors covered
- Market positioning of vendors
- Bayer AG
- Brainstorm Cell Therapeutics Inc.
- Daiichi Sankyo Co. Ltd.
- FUJIFILM Holdings Corp.
- Holostem Terapie Avanzate Srl
- Osiris Therapeutics Inc.
- Takeda Pharmaceutical Co. Ltd.
- Teva Pharmaceutical Industries Ltd.
- Sumitomo Chemical Co. Ltd.
- Vericel Corp.
Appendix
- Scope of the report
- Currency conversion rates for US$
- Research methodology
- List of abbreviations
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
